Researchers from the University of Oxford’s Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine.
Influenza is thought to be a highly variable virus, able to mutate and escape immunity built up in the population due to its circulation in previous seasons. However, influenza seasons tend to be dominated by a limited number of antigenically and genetically distinct influenza viruses. This creates a paradox as influenza is thought of as being highly variable while in reality influenza seasons are dominated by only a few strains.
Mathematical models produced in Professor Sunetra Gupta’s group at the University of Oxford over the past 20 years have sought to find an answer to this paradox. Finally, through a collaborative approach across multiple departments, the group believes they have the answer, demonstrated in a paper published today in Nature Communications.
Dr Craig Thompson said: ‘The integrated approach to vaccine design that we have applied to flu has to the potential to be applied to other previously intractable pathogens and could revolutionise the way we develop vaccines.’
Professor Sunetra Gupta said: ‘I think this work serves a good example of how evolutionary models can have translational impact. We have gone from a prediction of a mathematical model to a blueprint for a universal influenza vaccine. The outstanding teamwork coordinated by Dr Thompson is what made it all possible.’
The research team theorized that parts of the virus targeted by the immune system are, in fact, limited in variability and act as constraints on the evolution of the virus. Dr Craig Thompson in Professor Gupta’s group has now identified the location of these regions of limited variability. He has shown that such locations are targeted naturally by the immune system and through vaccination studies has shown that regions of influenza viruses that circulated in 2006 and 1977 were able to protect against infection with an influenza virus that last circulated in 1934.
The results of these studies can be exploited to create a novel type of ‘universal’ or broadly protective influenza vaccine, which once administered would provide lifelong protection against influenza. The team also hopes to apply the approach to other viruses such as HIV and HCV and believes that they can use it to produce a vaccine that protects against the common cold. The novel approach to vaccine design is outlined in the paper published in Nature Communications. Furthermore, such vaccines should be able to be produced in a low-cost manner, enabling healthcare providers such as the NHS to save money, unlike many new vaccines and drugs coming to the market.
This study also presents one of the first examples of where a mathematical model of the evolutionary dynamics of an infectious disease has led to the experimental identification of a novel vaccine target. The novel approach won an MRC Confidence in Concept Award in 2016, a Royal Society Translational Award in 2017 and an ERC Proof of Concept grant in 2018.
The WHO estimates that influenza kills 260,000-650,000 people and causes 3-5 million cases of severe illness each year. This burden typically falls on the elderly and young children, especially in developing countries. The best way to protect against influenza is through vaccination, although the problem with this is that the current influenza vaccine has to be administered each year and varies in its effectiveness.
The Latest on: Universal flu vaccine
via Google News
The Latest on: Universal flu vaccine
- Building a better flu vaccine -- one you don't have to get every yearon November 30, 2019 at 3:12 am
But a universal flu shot would theoretically cover every strain of the flu using what's known as an ice cream cone approach. Picture an ice cream shop that serves a wide variety of flavors, all served ...
- An experimental flu vaccine could radically change the shot you get every yearon November 29, 2019 at 9:54 am
The current flu vaccine takes aim at the ice cream, which changes all the time. The universal flu shot takes aim at the cone, which is a much better target, since it always stays the same.Last spring, ...
- How the flu vaccine is made each year to keep up with constantly mutating versions of the viruson November 28, 2019 at 5:00 am
But an annual flu shot could one day be a thing of the past. Researchers at the University of Washington School of Medicine’s Institute for Protein Design are working on a universal flu vaccine that ...
- Building a Better Flu Vaccine Or Designing a Universal Vaccine.on November 28, 2019 at 3:38 am
Getting a flu shot can reduce the chances of infection. The Michigan State University researcher's new work can aid to develop better future flu vaccines or design a universal vaccine. They have data ...
- Vaccitech announces successful recruitment and vaccination for two phase 2 Universal influenza studieson November 25, 2019 at 8:30 pm
Vaccitech Ltd, a clinical-stage T cell immunotherapy company developing products to treat and prevent cancer and infectious diseases, reports successful recruitment and vaccination for its Universal ...
- Expert column: The hunt for a universal flu vaccineon November 25, 2019 at 12:27 pm
This uncertainty is the driving force behind the push to develop a universal flu vaccine that would protect against all strains of influenza, regardless of what specific virus arises in a given year.
- Vaccitech provides update on clinical progress for its two Phase 2 Universal Influenza studieson November 25, 2019 at 12:06 am
Vaccitech progresses clinical development of Universal Influenza A Vaccine (VTP-100) in Belgium and Australia and expects top-line data in early 2020 Vaccitech Ltd, a clinical-stage T cell ...
- Hearing on the Flu Vaccineon November 21, 2019 at 2:23 pm
Experts on influenza testify before the House Science Committee on improving the flu vaccination.
- Enrollment and Randomization of 12,463 Participants Complete in BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine trialon November 18, 2019 at 3:15 am
JERUSALEM, Nov. 18, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced today that enrollment and randomization of 12,463 participants in the pivotal, clinical efficacy, Phase ...
via Bing News